Article Text

Download PDFPDF

BS60 Molecular mechanisms implicated in inhibition of angiogenesis mediated by the calcium transporter plasma membrane calcium ATPASE 4
  1. Reshma Naomi Ranjit Immanuel1,
  2. Satishkumar Kurusamy2,
  3. Nicholas Stafford3,
  4. Elizabeth Cartwright3,
  5. James Cotton4,
  6. Angel L Armesilla2
  1. 1University of Wolverhampton
  2. 2RIHS, FSE, University of Wolverhampton
  3. 3Division of Cardiovascular Sciences, University of Manchester, Manchester, UK
  4. 4Department of Cardiology, Heart and Lung Centre, New Cross Hospital, Wolverhampton, UK


Introduction Ischaemic heart disease is a leading cause of death worldwide. Myocardial Infarction (MI) is caused by insufficient or no supply of oxygen to the heart due to narrowing of cardiac blood vessels. This may cause the death of cardiomyocytes, fibroblast and endothelial cells and lead to cardiac hypertrophy, and ultimately heart failure. Although current surgical treatments based on mechanical revascularisation like coronary bypass, grafting, or angioplasty exist, the chances of recurrent heart failure is higher in these patients. Emerging studies show that formation of new capillaries and blood vessels in the ischaemic heart is a promising therapeutical approach to circumvent the occluded blood supply. Unfortunately, the promising results obtained in animal pre-clinical models by delivery of pro-angiogenic factors, such as vascular endothelial growth factor (VEGF), into the ischaemic heart, have failed to be translated into clinical practice. Therefore, there is an urgent need to refine current approaches of therapeutic angiogenesis in order to improve neovascularization processes in the ischaemic heart. The recent identification from our laboratory of Plasma Membrane Calcium ATPase 4 (PMCA4) as a negative regulator of VEGF-driven angiogenesis has prompted us to hypothesise that targeting PMCA4-regulated pro-angiogenic signalling pathways can be used to increase cardiac revascularisation and restore blood flow to the myocardium at risk.

Methods As a first attempt to elucidate the pro-angiogenic signalling pathways regulated by PMCA4, we have evaluated in this work the expression of genes related to Notch signalling in primary endothelial cells lacking PMCA4. Expression of PMCA4 in HUVEC was silenced by transfection with a siRNA specific for human PMCA4 (or non-target siRNA as control) and stimulated with VEGF. RNA isolated from control or PMCA4-silenced cells was used to screen an array of genes related to Notch signalling. Differences in gene expression were further validated by qPCR using TaqMan gene expression assays.

Results Our results demonstrate that siRNA-mediated PMCA4 gene knockdown in primary endothelial cells strongly enhances the VEGF-induced upregulation of DLL1 and Hey1 gene expression. Lack of PMCA4 did not alter the expression of other important Notch ligands involved in angiogenesis regulation such as DLL4, demonstrating the specificity of our data. These data indicate that PMCA4 acts as a negative regulator of the VEGF-induced expression of DLL1 and Hey1.

Conclusion These results suggest that PMCA4 negatively regulates Notch signaling activation in endothelial cells stimulated by the pro-angiogenic factor VEGF.

Conflict of interest None

  • PMCA4
  • VEGF
  • signalling

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.